Glutathione S-transferase P protects against cyclophosphamide-induced cardiotoxicity in mice

Toxicology and Applied Pharmacology

Volumn 285, Issue 2, 2015, Pages 136-148

  Conklin, Daniel J ^a,b   Haberzettl, Petra ^a,b   Jagatheesan, Ganapathy ^a,b   Baba, Shahid ^a,b   Merchant, Michael L ^a,b   Prough, Russell A ^a   Williams, Jessica D ^c   Prabhu, Sumanth D ^d   Bhatnagar, Aruni ^a,b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Acrolein; Apoptosis; Cardiotoxicity; Cytoxan; GSTP1; JNK c Jun

Indexed keywords

MUS;

ACROLEIN; ALKYLATING AGENT; CYCLOPHOSPHAMIDE; GLUTATHIONE TRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL; BLOOD PRESSURE; CHEMICALLY INDUCED; DRUG EFFECTS; ECHOCARDIOGRAPHY; ENZYMOLOGY; GENETICS; HEART DISEASES; HEART MUSCLE; KNOCKOUT MOUSE; MALE; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY;

ACROLEIN; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOOD PRESSURE; CYCLOPHOSPHAMIDE; ECHOCARDIOGRAPHY; GLUTATHIONE TRANSFERASE; HEART DISEASES; MALE; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCARDIUM;

EID: 84928319160     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2015.03.029     Document Type: Article

References (72)

1. Adler V., Pincus M.R. Effector peptides from glutathione-S-transferase-pi affect the activation of jun by jun-N-terminal kinase. Ann. Clin. Lab. Sci. 2004, 34:35-46.
2. Adler V., Yin Z., Fuchs S.Y., Benezra M., Rosario L., Tew K.D., Pincus M.R., Sardana M., Henderson C.J., Wolf C.R., Davis R.J., Ronai Z. Regulation of JNK signaling by GSTp. EMBO J. 1999, 18:1321-1334.
3. Alderton A.L., Faustman C., Liebler D.C., Hill D.W. Induction of redox instability of bovine myoglobin by adduction with 4-hydroxy-2-nonenal. Biochemistry 2003, 42:4398-4405.
4. Al-Rawithi S., El-Yazigi A., Ernst P., Al-Fiar F., Nicholls P.J. Urinary excretion and pharmacokinetics of acrolein and its parent drug cyclophosphamide in bone marrow transplant patients. Bone Marrow Transplant. 1998, 22:485-490.
5. Aplenc R., Blanco J., Leisenring W., Davies S., Relling M., Robison L., Sklar C., Stovall M., Bhatia S. Polymorphisms in candidate genes in patients with congestive heart failure (CHF) after childhood cancer: a report from the Childhood Cancer Survivor Study (CCSS). Proc. Am. Soc. Clin. Oncol. 2006, 24(18S):9004. (June 20 Supplement).
6. Awasthi S., Singhal S.S., Sharma R., Zimniak P., Awasthi Y.C. Transport of glutathione conjugates and chemotherapeutic drugs by RLIP76 (RALBP1): a novel link between G-protein and tyrosine kinase signaling and drug resistance. Int. J. Cancer 2003, 106:635-646.
7. Baba S.P., Hoetker J.D., Merchant M., Klein J.B., Cai J., Barski O.A., Conklin D.J., Bhatnagar A. Role of aldose reductase in the metabolism and detoxification of carnosine-acrolein conjugates. J. Biol. Chem. 2013, 288:28163-28179.
8. Batista C.K., Mota J.M., Souza M.L., Leitao B.T., Souza M.H., Brito G.A., Cunha F.Q., Ribeiro R.A. Amifostine and glutathione prevent ifosfamide- and acrolein-induced hemorrhagic cystitis. Cancer Chemother. Pharmacol. 2007, 59:71-77.
9. Berhane K., Widersten M., Engstrom A., Kozarich J.W., Mannervik B. Detoxication of base propenals and other alpha, beta-unsaturated aldehyde products of radical reactions and lipid peroxidation by human glutathione transferases. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:1480-1484.
10. Biagini R.E., Toraason M.A., Lynch D.W., Winston G.W. Inhibition of rat heart mitochondrial electron transport in vitro: implications for the cardiotoxic action of allylamine or its primary metabolite, acrolein. Toxicology 1990, 62:95-106.
11. Bryant B.M., Jarman M., Ford H.T., Smith I.E. Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet 1980, 2:657-659.
12. Conklin D.J., Boyce C.L., Trent M.B., Boor P.J. Amine metabolism: a novel path to coronary artery vasospasm. Toxicol. Appl. Pharmacol. 2001, 175:149-159.
13. Conklin D.J., Haberzettl P., Lesgards J.F., Prough R.A., Srivastava S., Bhatnagar A. Increased sensitivity of glutathione S-transferase P-null mice to cyclophosphamide-induced urinary bladder toxicity. J. Pharmacol. Exp. Ther. 2009, 331:456-469.
14. Conklin D.J., Haberzettl P., Prough R.A., Bhatnagar A. Glutathione-S-transferase P protects against endothelial dysfunction induced by exposure to tobacco smoke. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H1586-H1597.
15. Conklin D.J., Haberzettl P., Bertke M., Bhatnagar A. Role of glutathione S-transferase P (GSTP) in high fat diet-induced obesity: dissociation of endothelial dysfunction from insulin resistance. Circulation 2010, 122:A17917.
16. Cox P.J. Cyclophosphamide cystitis-identification of acrolein as the causative agent. Biochem. Pharmacol. 1979, 28:2045-2049.
17. Drimal J., Zurova-Nedelcevova J., Knezl V., Sotnikova R., Navarova J. Cardiovascular toxicity of the first line cancer chemotherapeutic agents: doxorubicin, cyclophosphamide, streptozotocin and bevacizumab. Neuroendocrinol. Lett. 2006, 27(Suppl. 2):176-179.
18. Ekhart C., Rodenhuis S., Smits P.H., Beijnen J.H., Huitema A.D. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet. Genomics 2008, 18:1009-1015.
19. Elsby R., Kitteringham N.R., Goldring C.E., Lovatt C.A., Chamberlain M., Henderson C.J., Wolf C.R., Park B.K. Increased constitutive c-Jun N-terminal kinase signaling in mice lacking glutathione S-transferase Pi. J. Biol. Chem. 2003, 278:22243-22249.
20. Faustman C., Liebler D.C., McClure T.D., Sun Q. Alpha, beta-unsaturated aldehydes accelerate oxymyoglobin oxidation. J. Agric. Food Chem. 1999, 47:3140-3144.
21. Freireich E.J. Who took the clinical out of clinical research? Mouse versus man: seventh David A Karnofsky Memorial Lecture-1976. Clin. Cancer Res. 1997, 3:2711-2722.
22. Friedman H.S., Colvin O.M., Aisaka K., Popp J., Bossen E.H., Reimer K.A., Powell J.B., Hilton J., Gross S.S., Levi R., et al. Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity. Cancer Res. 1990, 50:2455-2462.
23. Gate L., Majumdar R.S., Lunk A., Tew K.D. Increased myeloproliferation in glutathione S-transferase pi-deficient mice is associated with a deregulation of JNK and Janus kinase/STAT pathways. J. Biol. Chem. 2004, 279:8608-8616.
24. Gil-Ortega I., Carlos Kaski J. Diabetic miocardiopathy. Med. Clin. (Barc.) 2006, 127:584-594.
25. Giraud B., Hebert G., Deroussent A., Veal G.J., Vassal G., Paci A. Oxazaphosphorines: new therapeutic strategies for an old class of drugs. Expert Opin. Drug Metab. Toxicol. 2010, 6:919-938.
26. Green N., Weech M., Walters E. Localization and characterization of glutathione-s-transferase isozymes alpha, mu, and pi within the mouse vomeronasal organ. Neurosci. Lett. 2005, 375:198-202.
27. Haberzettl P., Vladykovskaya E., Srivastava S., Bhatnagar A. Role of endoplasmic reticulum stress in acrolein-induced endothelial activation. Toxicol. Appl. Pharmacol. 2009, 234:14-24.
28. Habig W.H., Pabst M.J., Jakoby W.B. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J. Biol. Chem. 1974, 249:7130-7139.
29. Henderson C.J., Smith A.G., Ure J., Brown K., Bacon E.J., Wolf C.R. Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:5275-5280.
30. Ismahil M.A., Hamid T., Haberzettl P., Gu Y., Chandrasekar B., Srivastava S., Bhatnagar A., Prabhu S.D. Chronic oral exposure to the aldehyde pollutant acrolein induces dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 2011, 301:H2050-H2060.
31. Jensen O.N., Shevchenko A., Mann M. Protein analysis by mass spectrometry. Protein Structure 1997, Oxford University Press, Oxford. T.E. Creighton (Ed.).
32. Katayama M., Imai Y., Hashimoto H., Kurata M., Nagai K., Tamita K., Morioka S., Furukawa Y. Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J. Cardiol. 2009, 54:330-334.
33. Keith R.J., Haberzettl P., Vladykovskaya E., Hill B.G., Kaiserova K., Srivastava S., Barski O., Bhatnagar A. Aldose reductase decreases endoplasmic reticulum stress in ischemic hearts. Chem. Biol. Interact. 2009, 178:242-249.
34. Kirpich I.A., Gobejishvili L.N., Bon Homme M., Waigel S., Cave M., Arteel G., Barve S.S., McClain C.J., Deaciuc I.V. Integrated hepatic transcriptome and proteome analysis of mice with high-fat diet-induced nonalcoholic fatty liver disease. J. Nutr. Biochem. 2011, 22:38-45.
35. Kuittinen T., Husso-Saastamoinen M., Sipola P., Vuolteenaho O., Ala-Kopsala M., Nousiainen T., Jantunen E., Hartikainen J. Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2005, 36:1077-1082.
36. Levine L.A., Richie J.P. Urological complications of cyclophosphamide. J. Urol. 1989, 141:1063-1069.
37. Lii C.K., Liu K.L., Cheng Y.P., Lin A.H., Chen H.W., Tsai C.W. Sulforaphane and alpha-lipoic acid upregulate the expression of the pi class of glutathione S-transferase through c-jun and Nrf2 activation. J. Nutr. 2010, 140:885-892.
38. Low J.E., Borch R.F., Sladek N.E. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis. Cancer Res. 1982, 42:830-837.
39. Ludeman S.M. The chemistry of the metabolites of cyclophosphamide. Curr. Pharm. Des. 1999, 5:627-643.
40. Luo J., Hill B.G., Gu Y., Cai J., Srivastava S., Bhatnagar A., Prabhu S.D. Mechanisms of acrolein-induced myocardial dysfunction: implications for environmental and endogenous aldehyde exposure. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H3673-H3684.
41. Lynch M.P., Faustman C. Effect of aldehyde lipid oxidation products on myoglobin. J. Agric. Food Chem. 2000, 48:600-604.
42. Maulik N. Effect of p38 MAP kinase on cellular events during ischemia and reperfusion: possible therapy. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H2302-H2303.
43. Morandi P., Ruffini P.A., Benvenuto G.M., La Vecchia L., Mezzena G., Raimondi R. Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7g/m2) cyclophosphamide. Bone Marrow Transplant. 2001, 28:277-282.
44. Morandi P., Ruffini P.A., Benvenuto G.M., Raimondi R., Fosser V. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant. 2005, 35:323-334.
45. Motoki N., Shimizu T., Akazawa Y., Saito S., Tanaka M., Yanagisawa R., Motoki H., Nakazawa Y., Sakashita K., Iwasaki Y., Shiohara M., Koike K. Increased pretransplant QT dispersion as a risk factor for the development of cardiac complications during and after preparative conditioning for pediatric allogeneic hematopoietic stem cell transplantation. Pediatr. Transplant. 2010, 14:986-992.
46. Olsson A.Y., Lundwall A. Organization and evolution of the glandular kallikrein locus in Mus musculus. Biochem. Biophys. Res. Commun. 2002, 299:305-311.
47. Pal A., Hu X., Zimniak P., Singh S.V. Catalytic efficiencies of allelic variants of human glutathione S-transferase Pi in the glutathione conjugation of alpha, beta-unsaturated aldehydes. Cancer Lett. 2000, 154:39-43.
48. Parikh H., Wang Z., Pettigrew K.A., Jia J., Daugherty S., Yeager M., Jacobs K.B., Hutchinson A., Burdett L., Cullen M., Qi L., Boland J., Collins I., Albert T.J., Vatten L.J., Hveem K., Njolstad I., Cancel-Tassin G., Cussenot O., Valeri A., Virtamo J., Thun M.J., Feigelson H.S., Diver W.R., Chatterjee N., Thomas G., Albanes D., Chanock S.J., Hunter D.J., Hoover R., Hayes R.B., Berndt S.I., Sampson J., Amundadottir L. Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels. Hum. Genet. 2011, 129:675-685.
49. Perini P., Calabrese M., Rinaldi L., Gallo P. The safety profile of cyclophosphamide in multiple sclerosis therapy. Expert. Opin. Drug Saf. 2007, 6:183-190.
50. Pope C.A., Renlund D.G., Kfoury A.G., May H.T., Horne B.D. Relation of heart failure hospitalization to exposure to fine particulate air pollution. Am. J. Cardiol. 2008, 102:1230-1234.
51. Roberts J.C., Francetic D.J., Zera R.T. Chemoprotection against cyclophosphamide-induced urotoxicity: comparison of nine thiol protective agents. Anticancer Res. 1994, 14:389-395.
52. Senkus E., Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat. Rev. 2011, 37:300-311.
53. Sharda S.V., Gulati S., Tripathi G., Jafar T., Kumar A., Sharma R.K., Agrawal S. Do glutathione-S-transferase polymorphisms influence response to intravenous cyclophosphamide therapy in idiopathic nephrotic syndrome?. Pediatr. Nephrol. 2008, 23:2001-2006.
54. Sharma M., Moulder J.E. The urine proteome as a radiation biodosimeter. Adv. Exp. Med. Biol. 2013, 990:87-100.
55. Shepherd J.D., Pringle L.E., Barnett M.J., Klingemann H.G., Reece D.E., Phillips G.L. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J. Clin. Oncol. 1991, 9:2016-2020.
56. Sklar J.L., Anderson P.G., Boor P.J. Allylamine and acrolein toxicity in perfused rat hearts. Toxicol. Appl. Pharmacol. 1991, 107:535-544.
57. Sladek N.E. Metabolism and pharmacokinetic behavior of cyclophosphamide and related oxazaphosphorines 1994, 79-156.
58. Srivastava S., Chandrasekar B., Bhatnagar A., Prabhu S.D. Lipid peroxidation-derived aldehydes and oxidative stress in the failing heart: role of aldose reductase. Am. J. Physiol. Heart Circ. Physiol. 2002, 283:H2612-H2619.
59. Steinkellner H., Hoelzl C., Uhl M., Cavin C., Haidinger G., Gsur A., Schmid R., Kundi M., Bichler J., Knasmuller S. Coffee consumption induces GSTP in plasma and protects lymphocytes against (+/-)-anti-benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide induced DNA-damage: results of controlled human intervention trials. Mutat. Res. 2005, 591:264-275.
60. Swaney D.L., McAlister G.C., Coon J.J. Decision tree-driven tandem mass spectrometry for shotgun proteomics. Nat. Methods 2008, 5:959-964.
61. Syed F., Diwan A., Hahn H.S. Murine echocardiography: a practical approach for phenotyping genetically manipulated and surgically modeled mice. J. Am. Soc. Echocardiogr. 2005, 18:982-990.
62. Takamoto S., Sakura N., Namera A., Yashiki M. Monitoring of urinary acrolein concentration in patients receiving cyclophosphamide and ifosphamide. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2004, 806:59-63.
63. Tenhunen O., Rysa J., Ilves M., Soini Y., Ruskoaho H., Leskinen H. Identification of cell cycle regulatory and inflammatory genes as predominant targets of p38 mitogen-activated protein kinase in the heart. Circ. Res. 2006, 99:485-493.
64. Toraason M., Luken M.E., Breitenstein M., Krueger J.A., Biagini R.E. Comparative toxicity of allylamine and acrolein in cultured myocytes and fibroblasts from neonatal rat heart. Toxicology 1989, 56:107-117.
65. Vladykovskaya E., Sithu S.D., Haberzettl P., Wickramasinghe N.S., Merchant M.L., Hill B.G., McCracken J., Agarwal A., Dougherty S., Gordon S.A., Schuschke D.A., Barski O.A., O'Toole T., D'Souza S.E., Bhatnagar A., Srivastava S. Lipid peroxidation product 4-hydroxy-trans-2-nonenal causes endothelial activation by inducing endoplasmic reticulum stress. J. Biol. Chem. 2012, 287:11398-11409.
66. Wetzelberger K., Baba S.P., Thirunavukkarasu M., Ho Y.S., Maulik N., Barski O.A., Conklin D.J., Bhatnagar A. Postischemic deactivation of cardiac aldose reductase: role of glutathione S-transferase P and glutaredoxin in regeneration of reduced thiols from sulfenic acids. J. Biol. Chem. 2010, 285:26135-26148.
67. Worth L., Tran H., Petropoulos D., Culbert S., Mullen C., Roberts W., Przepiorka D., Chan K. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide. Bone Marrow Transplant. 1999, 24:947-952.
68. Wu Y., Fan Y., Xue B., Luo L., Shen J., Zhang S., Jiang Y., Yin Z. Human glutathione S-transferase P1-1 interacts with TRAF2 and regulates TRAF2-ASK1 signals. Oncogene 2006, 25:5787-5800.
69. Xue B., Wu Y., Yin Z., Zhang H., Sun S., Yi T., Luo L. Regulation of lipopolysaccharide-induced inflammatory response by glutathione S-transferase P1 in RAW264.7 cells. FEBS Lett. 2005, 579:4081-4087.
70. Yu L.J., Drewes P., Gustafsson K., Brain E.G., Hecht J.E., Waxman D.J. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity. J. Pharmacol. Exp. Ther. 1999, 288:928-937.
71. Zver S., Zadnik V., Bunc M., Rogel P., Cernelc P., Kozelj M. Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int. J. Hematol. 2007, 85:408-414.
72. Zver S., Zadnik V., Cernelc P., Kozelj M. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Int. J. Hematol. 2008, 88:227-236.